Trending menu:
AstraZeneca’s Farxiga (dapagliflozin) has met the primary endpoint in Phase III DAPA-HF study involving patients with reduced ejection fraction (HFrEF), with or without type 2 diabetes.
UK-based biotechnology firm Redx Pharma has received a recommendation from a safety review committee to continue the evaluation of its cancer asset, RXC004, in an ongoing Phase I/II clinical trial.
A new study in the US has found that less than 8% of oncology clinical trials over the past decade featured participants from the country's major races.
Mallinckrodt has reported positive data from the Phase III CONFIRM trial of terlipressin conducted in hepatorenal syndrome type 1 (HRS-1) patients.
IQVIA has launched a new web-based solution to offer patients a direct access point for clinical trial information following their enrolment.
US-based data-driven clinical trials provider Medable is set to join the American Heart Association’s Center for Health Technology & Innovation Innovators Network to improve a patient-centric digital system that connects...
AstraZeneca and MSD have reported that the Phase III PAOLA-1 study of Lynparza (olaparib) in combination with bevacizumab met the primary endpoint in advanced ovarian cancer patients.
Eli Lilly has reported that the Phase IV IXORA-R clinical trial of Taltz (ixekizumab) met the primary and key secondary endpoints up to week 12.
Deciphera Pharmaceuticals has announced positive findings from the Phase III INVICTUS clinical trial that evaluated ripretinib for the treatment of fourth-line and fourth-line plus gastrointestinal stromal tumours (GIST).
Signant Health has launched a new partner programme to collaborate with clinical research organisations (CROs) in a bid to improve clinical trials with patient-centric technology.
